Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease
What is the purpose of this trial?
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the effect of gantenerumab (RO4909832) on cognition and functioning and the safety and pharmacokinetics in subjects with prodromal Alzheimer's Disease. ; Subject will be randomized to receive subcutaneous injections of either gantenerumab or placebo. ; The anticipated time on study treatment is 104 weeks.
- Hoffman-La Roche
- Last Updated:
- Study HIC#: